Ghrelin News and Research

RSS

Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. Ghrelin is also produced in the hypothalamic arcuate nucleus where it stimulates the secretion of growth hormone from the anterior pituitary gland.

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Proteins causing daytime sleepiness also play crucial role in bone formation

Orexin proteins, which are blamed for spontaneous daytime sleepiness, also play a crucial role in bone formation, according to findings by UT Southwestern Medical Center researchers.

13 Jun 2014

People with obesity gene FTO tend to gain more weight as they age

A new study from Uppsala University demonstrates that elderly humans carrying a common variant of the fat mass and obesity gene FTO also have a shifted endocrine balance. Low blood concentrations of the satiety hormone leptin and high blood concentrations of the hunger promoting hormone ghrelin makes carriers of the FTO gene put on weight.

12 Jun 2014

New data shows adult America is 55% obese, not 35%

On the heels of the wake-up call from 'FED UP', the just released documentary on obesity, it is no surprise that the CDC's (U.S. Center for Disease Control) obesity statistics are grossly under reported. Meredith

6 Jun 2014

Yale researchers find that hormone leptin may help treat metabolic disorders

Twenty years after the hormone leptin was found to regulate metabolism, appetite, and weight through brain cells called neurons, Yale School of Medicine researchers have found that the hormone also acts on other types of cells to control appetite.

2 Jun 2014

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression.

23 Apr 2014

Wen Dan Tang significantly reduces insomnia-related anxiety

Ghrelin, a brain-gut peptide that induces anxiety and other abnormal emotions, contributes to the effects of insomnia on emotional behavior. In contrast, the traditional Chinese Medicine remedy Wen Dan Tang reduces insomnia-related anxiety, which may perhaps correspond to changes in the brain-gut axis.

1 Apr 2014

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center is among about a dozen centers nationally exploring the potential of a new drug that may offer relief to people with Parkinson's who have failed standard approaches to treating constipation.

5 Mar 2014

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

7 Jan 2014

Obesity is an expensive problem, says bariatric surgeon

As a preeminent expert in the field of obesity surgery, board-certified bariatric surgeon Michael Feiz, M.D., F.A.C.S, has personally seen the physical, emotional and financial toll that obesity takes on his patients.

31 Dec 2013

Embolizing left gastric artery may be potential bariatric treatment for weight loss

26 Nov 2013

Transarterial embolization procedure helps reduce body weight

A new study reports that individuals who underwent embolization of the left gastric artery for gastrointestinal bleeding experienced a 7.9 percent decrease in body weight three months after the procedure. Results of the study, which offer a potential new avenue for obesity research, will be presented next week at the annual meeting of the Radiological Society of North America.

25 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

The statistic that you often hear is that 95% of diets fail, but in actual fact, emerging research is now showing that it’s around 70% of diets that fail. That means that around 30% of people who are losing weight are actually keeping it off. So we’re doing better now than we were doing in the past, but there’s still work to be done.

7 Nov 2013

Aeterna Zentaris submits macimorelin acetate NDA to FDA

Aeterna Zentaris Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration ("FDA") for its ghrelin agonist, macimorelin acetate (AEZS-130).

5 Nov 2013

Researchers highlight presence of specific antibodies that regulate appetite in obese patients

Obesity affects more than 15% of adults in France, and its constitutive mechanisms are still not completely explained. Normally, fine control of weight and food intake is coordinated by a specialised part of the brain (the hypothalamus).

31 Oct 2013

Ghrelin hormone released during chronic stress may predispose people to PTSD

About a dozen years ago, scientists discovered that a hormone called ghrelin enhances appetite. Dubbed the "hunger hormone," ghrelin was quickly targeted by drug companies seeking treatments for obesity - none of which have yet panned out.

16 Oct 2013

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.

24 Sep 2013

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease.